Neuralink implantable device involved in can-prime study

​​​​​​​​​​​"As the first and exclusive surgical site in Canada to perform this procedure, we will be continuing to shape the future of neurological care and further defining our track record for doing what hasn’t been done," Dr. Kevin Smith, UHN's President & CEO, says of UHN's selection as Canadian site for the CAN-PRIME study, a clinical trial involving the Neuralink implantable device. (Photo: UHN)​

It's been another extraordinary year at Canada's No. 1 Hospital. There were many milestones and achievements in clinical care for patients and families, across research and in education. UHN News is taking a look back at some of our top stories.

​​​​
Quicklinks
Back to Top